Preclinical models with MCF7 xenografts engineered to overexpress aromatase (Brodie et al, 2003), as well as models of tamoxifen-dependent tumour growth (Gottardis and Jordan, 1988), support this explanation for the therapeutic advantage of AIs. This evidence concerns the gene CYP19A1 and neoplasm.